| FDA clears Pfizer drug for advanced kidney cancer - Wall Street Journal |
|
|
Wall Street Journal The Food and Drug Administration approved the company's drug Inlyta as a secondary option for patients with renal cell carcinoma that hasn't responded to previous drug treatments. Renal cell carcinoma is the most common form of kidney cancer, |